Navigation Links
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
Date:6/3/2008

age clinical studies," said Mr. Swisher.

Actions taken today will allow the company to direct most of its resources into the late-stage development of voreloxin. Sunesis expects this realignment of personnel and programs to reduce annual operating expenses by more than $15 million, thus enabling increased investment into such development. Current burn rate guidance for the second half of 2008 is in the range of $12-15 million, including payment of severance and other restructuring charges.

About Voreloxin (formerly SNS-595)

Sunesis' lead compound, voreloxin (formerly SNS-595), is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication- dependent, site-selective DNA damage, irreversible G2 arrest and rapid apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients, in a Phase 1b clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, and as a single agent in a Phase 2 clinical trial in platinum-resistant ovarian cancer. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the development of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
2. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
3. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
4. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
7. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
8. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
9. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
10. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Wash. , Sept. 16, 2014 /PRNewswire/ ... a late stage development company engaged primarily ... medical isotopes for diagnostic and therapeutic applications, ... for technology related to its brachytherapy products.  ... arise from its license from Battelle, under ...
(Date:9/16/2014)... -- Russia,s pharmaceutical ... Pharma 2020 Strategy provides incentives for local producers to ... foreign markets. These trends, however, were affected by recent ... political and economic sanctions imposed on Russia ... Russia responded to the US ...
(Date:9/16/2014)... Sept. 16, 2014 Surgeons at The Children,s ... a case report the first successful use of a ... year-old boy with failing Fontan circulation to bridge him ... 3 years old, the patient received a Fontan circulation ... single ventricle. "The Fontan operation is the final planned ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4Global Medicines for Russia 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 213-Year-Old Boy with Failed Fontan Circulation Bridged to Transplant Using the SynCardia Total Artificial Heart, Published in Annals of Thoracic Surgery 3
... According to new data from,PAREXEL International Corporation (Nasdaq: ... the number of new,industry-sponsored clinical trial initiations, or ... in 2007. PAREXEL,s analysis shows that the,biopharmaceutical industry ... support of new clinical studies for drugs in,2007, ...
... June 20 GlaxoSmithKline,(NYSE: GSK ) today ... has extended the priority review period for PROMACTA(R),(eltrombopag) ... chronic idiopathic thrombocytopenic purpura, as they require more ... Fee action date has,been extended to September 19, ...
Cached Medicine Technology:PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 2PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 3PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 4PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated 5GSK Update on FDA Review of Promacta(R) (Eltrombopag) 2
(Date:9/16/2014)... Sept. 16, 2014 (HealthDay News) -- Modern forensic techniques ... injuries might have killed King Richard III, the last ... analysis of the king,s skeletal remains, using whole-body CT ... detailed account of the 11 injuries he suffered at ... Aug. 22, 1485. The modern forensics revealed that ...
(Date:9/16/2014)... Advanced Fertility Center of Texas’ Dr. Michael ... one of the Top Doctors of 2014. The annual ... magazine serving the Houston area. They award esteemed doctors ... outstanding services. This accomplishment will be included in the ... a special publication listing all the winners of the ...
(Date:9/16/2014)... These new programs allow those who haven’t owned a ... $10,000 in a 0% interest free, 2nd down payment assistance ... federal programs, are listed on their private website. The $10,000 ... or move out of the property. The down payment assistance ... no monthly payments paid by the Borrower. The money is ...
(Date:9/16/2014)... Denver, CO (PRWEB) September 16, 2014 ... today that it has been recognized for its high ... published Consulting magazine “The Best Small Firms to Work ... Firms survey annually, with more than 10,000 consultants participating ... Extensive employee satisfaction surveys were conducted, and firms ...
(Date:9/16/2014)... A new clinical trial comparing the ... balloons (DEB) in treating in-stent restenosis (ISR) ... superior late angiographic results and better late ... today at the 26th annual Transcatheter Cardiovascular ... Cardiovascular Research Foundation (CRF), TCT is the ...
Breaking Medicine News(10 mins):Health News:Modern Forensics Provides Clues to Death of Richard III 2Health News:Dr. Michael Allon Receives Esteemed Recognition 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 2Health News:New Updated 2014 First Time Home Buyer Programs Available to Florida Residents 3Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 2Health News:Aspen Advisors Earns Recognition in Consulting Magazine’s "Best Small Firms to Work For" 3Health News:Results of RIBS IV trial reported at TCT 2014 2
... drugs and end up in the ER, CDC says , ... accidental poisonings among American children can be found in the ... year in the United States, more than 71,000 children aged ... overdoses of prescription and over-the-counter drugs, the researchers found. , ...
... , , RANCHO CORDOVA, ... Blindness America announced today the results of their joint nationwide survey ... five 12 to 17-year-olds have difficulty seeing the classroom whiteboard/chalkboard, with ... noted even though nearly half (45 percent) of the children in ...
... , , PALM CITY, Fla., Aug. 4 ... pleased to announce that the Company has formed a partnership ... company. The agreement will enable InstantAmber to offer the ... a valuable information tool that gives parents the ability to ...
... , SADDLE BROOK, N.J., Aug. 4 ... ) is the only hospital in New Jersey and one ... amputees the new PROPRIO FOOT(R), a prosthesis that provides greater ... developed by Ossur, a global leader in orthopedic products, closely ...
... , , , GLENWOOD, Ill., ... recognized leader in personal and environmental radiation monitoring services, today reported financial results ... , Fiscal 2009 Third Quarter Highlights , ... $23.5 million on continued global demand for InLight products and increased domestic badge ...
... Inc. (OTC BB:ALRX.OB - News), an emerging biopharmaceutical company ... of drugs, today announced that the Company has entered ... to establish a drug development center in China Medical ... as a platform for the development of innovative drug ...
Cached Medicine News:Health News:Medicines Top Source of Kids' Poisonings 2Health News:Medicines Top Source of Kids' Poisonings 3Health News:Medicines Top Source of Kids' Poisonings 4Health News:More Than One in Five 12 to 17-Year-Olds Have Trouble Seeing in Class 2Health News:More Than One in Five 12 to 17-Year-Olds Have Trouble Seeing in Class 3Health News:More Than One in Five 12 to 17-Year-Olds Have Trouble Seeing in Class 4Health News:Connectyx Partners with InstantAmber, a Leader in Child Safety and Missing Children Awareness 2Health News:Connectyx Partners with InstantAmber, a Leader in Child Safety and Missing Children Awareness 3Health News:Kessler Institute for Rehabilitation Only Hospital in New Jersey to Offer New Bionic Foot to Amputees 2Health News:Kessler Institute for Rehabilitation Only Hospital in New Jersey to Offer New Bionic Foot to Amputees 3Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 2Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 3Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 4Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 5Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 6Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 7Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 8Health News:Landauer, Inc. Reports Fiscal 2009 Third Quarter Results 9Health News:AlphaRx and Venturepharm Announce Collaboration Agreement 2
19 Gauge. Reusable. Block of 4 each....
18 gauge curved. Fine tip. Lightweight design offers precise hemostasis. Pencil design minimizes tissue trauma and induced astigmatism. Knurled handle provides a sure grip and better manipulation....
Set consist of two 23 gauge, stainless steel probes with blunt tips. Probes are 18 cm (7.0 inches) long with 30.5 cm (12 inches) of flexible tubing (O.D. - 0.60 mm, I.D. - 0.30 mm) attached onto the ...
Curved, soft flexible tip allows atraumatic entry through a retinal tear or hole for aspiration of subretinal fluids. 20 gauge x 25 mm cannula attached to 25 gauge x 6 mm tip with 13 mm flexible tubi...
Medicine Products: